Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 6, 2016, Pages

  Gross, Catharina C ^a   Ahmetspahic, Diana ^b,c   Ruck, Tobias ^a   Mecklenbeck, Andreas Schulte ^a   Schwarte, Kathrin ^b,c   Jörgens, Silke ^b   Scheu, Stefanie ^d   Windhagen, Susanne ^e   Graefe, Bettina ^e   Melzer, Nico ^a   Klotz, Luisa ^a   Arolt, Volker ^b   Wiendl, Heinz ^a,c   Meuth, Sven G ^a,c   Alferink, Judith ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Department of Psychiatry ^*  (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e Department of Neurology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 23;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; T LYMPHOCYTE SUBPOPULATION; YOUNG ADULT;

EID: 85009381293     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000289     Document Type: Article

References (32)

1. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35:118-127.
2. Rao SP, Sancho J, Campos-Rivera J, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012;7:e39416.
3. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009;128:260-270.
4. Mone AP, Cheney C, Banks AL, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006;20:272-279.
5. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010;327:656-661.
6. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011;12:21-27.
7. Gross CC, Wiendl H. Dendritic cell vaccination in autoimmune disease. Curr Opin Rheumatol 2013;25:268-274.
8. Zozulya AL, Clarkson BD, Ortler S, Fabry Z, Wiendl H. The role of dendritic cells in CNS autoimmunity. J Mol Med2010;88:535-544.
9. Poppensieker K, Otte DM, Schurmann B, et al. CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells. Proc Natl Acad Sci USA 2012; 109:3897-3902.
10. Perry JS, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med 2012;4:145ra106.
11. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103: 5941-5946.
12. Laroni A, Armentani E, Kerlero de Rosbo N, et al. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis. J Autoimmun 2016;72:8-18.
13. Gross CC, Schulte-Mecklenbeck A, Rünzi A, et al. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc Natl Acad Sci USA 2016;113:E2973-E2982.
14. Posevitz-Fejfar A, Posevitz V, Gross CC, et al. Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: implications for immune cell biobanking. PLoS One 2014;9:e115920.
15. Schulte-Mecklenbeck A, Bittner S, Ehling P, et al. The twopore domain K2 P channel TASK2 drives human NK-cell proliferation and cytolytic function. Eur J Immunol 2015; 45:2602-2614.
16. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001;97:3146-3151.
17. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002;100:1715-1720.
18. Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002;99:2586-2591.
19. Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood 2002; 99:1442-1448.
20. Chklovskaia E, Nowbakht P, Nissen C, Gratwohl A, Bargetzi M, Wodnar-Filipowicz A. Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand. Blood 2004;103:3860-3868.
21. Gross CC, Jonuleit H, Wiendl H. Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis. Eur J Immunol 2012;42:569-572.
22. Ganguly D, Haak S, Sisirak V, Reizis B. The role of dendritic cells in autoimmunity. Nat Rev Immunol 2013;13:566-577.
23. Karni A, Abraham M, Monsonego A, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006;177:4196-4202.
24. Vaknin-Dembinsky A, Murugaiyan G, Hafler DA, Astier AL, Weiner HL. Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. J Neuroimmunol 2008;195:140-145.
25. Schwab N, Zozulya AL, Kieseier BC, Toyka KV, Wiendl H. An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis. J Immunol 2010;184:5368-5374.
26. Klotz L, Wiendl H. Monoclonal antibodies in neuroinflammatory diseases. Expert Opin Biol Ther 2013;13:831-846.
27. Wiendl H, Gross CC. Modulation of IL-2Ralpha with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol 2013;9:394-404.
28. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2015;373:1418-1428.
29. Rizzo R, Zatelli MC, Rotola A, et al. Increase in peripheral CD3(-)CD56(bright)CD16(-) natural killer cells in Hashimoto's thyroiditis associated with HHV-6 infection. Adv Exp Med Biol 2016;897:113-120.
30. Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci 2015;16:16414-16439.
31. Obermann M, Ruck T, Pfeuffer S, Baum J, Wiendl H, Meuth SG. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis. Mult Scler 2016;22:1235-1241.
32. Abeles RD, McPhail MJ, Sowter D, et al. CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi)/CD16(neg) monocytes: expansion of CD14(hi)/CD16(pos) and contraction of CD14(lo)/CD16 (pos) monocytes in acute liver failure. Cytometry A 2012; 81:823-834.